Story thread · 4 reports / 2 sources

GSK’s Ris-Rez shows survival benefit in lung cancer trial

investing.com · 1dShare

First report: Zipalertinib + chemo meets primary endpoint in phase III REZILIENT3 trial in first-line EGFR exon 20 insertion mutation NSCLC — cancerletter.com, 3d